Diagnosing non-small cell lung cancer by exhaled-breath profiling using an electronic nose: a multicentre validation study.
Sharina Kort,Marjolein Brusse-Keizer,Emanuel Citgez,Ben van den Borne,Daiana Stolz,Milou Schuurbiers,Job van der Palen,Dr. Hugo Schouwink,Frans de Jongh,John van Putten,Lisanne Kastelijn,Michel van den Heuvel,Wouter H. van Geffen
DOI: https://doi.org/10.1016/j.chest.2022.09.042
IF: 9.6
2022-10-15
Chest
Abstract:Background Despite the potential of exhaled-breath analysis of volatile organic compounds to diagnose lung cancer, clinical implementation has not been realized partly due to the lack of validation studies. Research question This study addressed two questions: 1) Can we simultaneously train and validate a prediction model to distinguish non-small cell lung cancer (NSCLC) patients from non-lung cancer subjects based on exhaled-breath patterns? 2) Does addition of clinical variables to exhaled-breath data improve the diagnosis of lung cancer? Study design and methods In this multicentre study, subjects with NSCLC and control subjects, performed a measurement of 5 minutes of breathing in the AeonoseTM. A training cohort was used for developing a prediction model based on breath data, whereas a blinded cohort was used for validation. Multivariable logistic regression analysis was performed including breath data and clinical variables, where the formula and cut-off value for the probability of lung cancer were applied on the validation data. Results 376 Subjects formed the training, and 199 subjects formed the validation set. The full training model, including clinical parameters and breath data showed, at a cut-off probability of 16% for lung cancer, a sensitivity of 95%, specificity of 51%, a negative predictive value (NPV) of 94% with an area under the receiver operating characteristic curve (AUC) of 0.87. Performance of the prediction model on the validation cohort showed corresponding results with a sensitivity of 95%, specificity of 49%, NPV of 94%, and an AUC of 0.86. Interpretation Combining exhaled-breath data and clinical variables in a multicentre, multi-device validation study can adequately distinguish lung cancer patients from subjects without lung cancer in a non-invasive manner. This study paves the way to implement exhaled-breath analysis in the daily practice of diagnosing lung cancer. Trial Registration Number The Netherlands Trial Register, NL7025
respiratory system,critical care medicine